Table 2.
Landscape of viral vector candidate vaccines in late clinical development for COVID-19.
| Vaccine Candidate | Viral Vector | Platform | Administration Route | Developers | Clinical Trials |
|---|---|---|---|---|---|
| ChAdOx1-S (AZD1222) | Chimpanzee adenovirus | VVnr | IM | Oxford/AstraZeneca | Phase 4 |
| Convidecia(Ad5-nCoV) | Adenovirus type 5 | VVnr | IM/IH | CanSino/Chinese Academy of Military Medical Sciences | Phase 4 |
| Sputnik V (rAd26-S+rAd5-S) | Adenovirus 26 and adenovirus 5 | VVnr | IM | Gamaleya Research Institute/Health Ministry of the Russian Federation | Phase 3 |
| Ad26.COV2.S | Adenovirus 26 | VVnr | IM | Johnson & Johnson | Phase 4 |
| GRAd-COV2 | Gorilla Adenovirus | VVnr | IM | ReiThera Srl/Lazzaro Spallanzani National Institute for Infectious Diseases | Phases 2/3 |
| DelNS1-2019-nCoV-RBD-OPT1 | Influenza virus | VVr | IN | University of Hong Kong/Xiamen University/Beijing Wantai | Phase 3 |
| IIBR-100 (rVSV-SARS-CoV-2-S) | Vesicular stomatitis virus | VVr | IM | Israel Institute for Biological Research | Phases 2/3 |
| BBV154 | Chimpanzee adenovirus | VVnr | IN | Bharat Biotech | Phase 3 |
| NDV-HXP-S | Newcastle Disease virus | VVr | IN/IM | Sean Liu, Icahn School of Medicine at Mount Sinai | Phases 2/3 |
VVnr: viral vector (non-replicating); VVr: viral vector (replicating); IM: intramuscular; IN: intranasal; IH: inhaled.